191 related articles for article (PubMed ID: 36556972)
21. Chromoendoscopy with a Standard-Resolution Colonoscope for Evaluation of Rectal Aberrant Crypt Foci.
Kowalczyk M; Siermontowski P; Mucha D; Ambroży T; Orłowski M; Zinkiewicz K; Kurpiewski W; Paśnik K; Kowalczyk I; Pedrycz A
PLoS One; 2016; 11(2):e0148286. PubMed ID: 26886097
[TBL] [Abstract][Full Text] [Related]
22. Biology and diagnosis of aberrant crypt foci.
Lopez-Ceron M; Pellise M
Colorectal Dis; 2012 Apr; 14(4):e157-64. PubMed ID: 22182185
[TBL] [Abstract][Full Text] [Related]
23. Histomorphology of aberrant crypt foci in colorectal carcinoma.
Norlida AO; Phang KS
Malays J Pathol; 2010 Dec; 32(2):111-6. PubMed ID: 21329182
[TBL] [Abstract][Full Text] [Related]
24. Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.
Quintanilla I; López-Cerón M; Jimeno M; Cuatrecasas M; Zabalza M; Moreira L; Alonso V; Rodríguez de Miguel C; Muñoz J; Castellvi-Bel S; Llach J; Castells A; Balaguer F; Camps J; Pellisé M
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00047. PubMed ID: 31136360
[TBL] [Abstract][Full Text] [Related]
25. Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
Higurashi T; Ashikari K; Tamura S; Saigusa Y; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Kessoku T; Hosono K; Yoneda M; Nakajima A
Cancer Prev Res (Phila); 2022 Oct; 15(10):661-668. PubMed ID: 36083855
[TBL] [Abstract][Full Text] [Related]
26. Aberrant crypt foci: endoscopic assessment and cell kinetics characterization.
Figueiredo P; Donato M; Urbano M; Goulão H; Gouveia H; Sofia C; Leitão M; Freitas D
Int J Colorectal Dis; 2009 Apr; 24(4):441-50. PubMed ID: 18769883
[TBL] [Abstract][Full Text] [Related]
27. Aberrant crypt focus size predicts distal polyp histopathology.
Kim J; Ng J; Arozulllah A; Ewing R; Llor X; Carroll RE; Benya RV
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1155-62. PubMed ID: 18483337
[TBL] [Abstract][Full Text] [Related]
28. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
Shpitz B; Klein E; Buklan G; Neufeld D; Nissan A; Freund HR; Grankin M; Bernheim J
Gut; 2003 Nov; 52(11):1598-601. PubMed ID: 14570729
[TBL] [Abstract][Full Text] [Related]
29. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease.
Bouzourene H; Chaubert P; Seelentag W; Bosman FT; Saraga E
Hum Pathol; 1999 Jan; 30(1):66-71. PubMed ID: 9923929
[TBL] [Abstract][Full Text] [Related]
30. A multicenter study of prevalence and risk factors for aberrant crypt foci.
Mutch MG; Schoen RE; Fleshman JW; Rall CJ; Dry S; Seligson D; Charabaty A; Chia D; Umar A; Viner J; Hawk E; Pinsky PF
Clin Gastroenterol Hepatol; 2009 May; 7(5):568-74. PubMed ID: 19418605
[TBL] [Abstract][Full Text] [Related]
31. Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.
Ohkubo H; Takahashi H; Yamada E; Sakai E; Higurashi T; Uchiyama T; Hosono K; Endo H; Taguri M; Nakajima A
Oncol Rep; 2012 May; 27(5):1475-80. PubMed ID: 22246586
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
33. Identification of High-Risk Aberrant Crypt Foci and Mucin-Depleted Foci in the Human Colon With Study of Colon Cancer Stem Cell Markers.
Gupta B; Das P; Ghosh S; Manhas J; Sen S; Pal S; Sahni P; Upadhyay AD; Panda SK; Gupta SD
Clin Colorectal Cancer; 2017 Sep; 16(3):204-213. PubMed ID: 27789195
[TBL] [Abstract][Full Text] [Related]
34. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
35. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population.
Moxon D; Raza M; Kenney R; Ewing R; Arozullah A; Mason JB; Carroll RE
Clin Gastroenterol Hepatol; 2005 Mar; 3(3):271-8. PubMed ID: 15765447
[TBL] [Abstract][Full Text] [Related]
36. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics.
Shpitz B; Bomstein Y; Mekori Y; Cohen R; Kaufman Z; Neufeld D; Galkin M; Bernheim J
Hum Pathol; 1998 May; 29(5):469-75. PubMed ID: 9596270
[TBL] [Abstract][Full Text] [Related]
37. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon.
Paulsen JE; Steffensen IL; Løberg EM; Husøy T; Namork E; Alexander J
Cancer Res; 2001 Jul; 61(13):5010-5. PubMed ID: 11431334
[TBL] [Abstract][Full Text] [Related]
38. A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.
Gillen DL; Meyskens FL; Morgan TR; Zell JA; Carroll R; Benya R; Chen WP; Mo A; Tucker C; Bhattacharya A; Huang Z; Arcilla M; Wong V; Chung J; Gonzalez R; Rodriguez LM; Szabo E; Rosenberg DW; Lipkin SM
Cancer Prev Res (Phila); 2015 Mar; 8(3):222-30. PubMed ID: 25604134
[TBL] [Abstract][Full Text] [Related]
39. Genetic and epigenetic changes in aberrant crypt foci and serrated polyps.
Suehiro Y; Hinoda Y
Cancer Sci; 2008 Jun; 99(6):1071-6. PubMed ID: 18384435
[TBL] [Abstract][Full Text] [Related]
40. One year recurrence of aberrant crypt foci.
Pinsky PF; Fleshman J; Mutch M; Rall C; Charabaty A; Seligson D; Dry S; Umar A; Schoen RE
Cancer Prev Res (Phila); 2010 Jul; 3(7):839-43. PubMed ID: 20570885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
